{"id":"covid-19-vaccination","safety":{"commonSideEffects":[{"rate":"50–70","effect":"Injection site pain or swelling"},{"rate":"30–50","effect":"Fatigue"},{"rate":"30–50","effect":"Headache"},{"rate":"20–40","effect":"Myalgia"},{"rate":"10–30","effect":"Fever"},{"rate":"10–20","effect":"Chills"},{"rate":"5–10","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"COVID-19 vaccines work by introducing viral antigen (either mRNA encoding spike protein, inactivated virus, or viral vector) to stimulate both humoral and cellular immune responses. This priming enables rapid recognition and clearance of SARS-CoV-2 upon exposure, reducing severity of infection and transmission. Multiple vaccine platforms have been deployed globally, including mRNA (Pfizer-BioNTech, Moderna), viral vector (AstraZeneca, Johnson & Johnson), and inactivated virus vaccines.","oneSentence":"COVID-19 vaccines train the immune system to recognize and neutralize the SARS-CoV-2 virus by inducing antibody and T-cell responses against viral antigens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:31:32.633Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/COVID-19_vaccine","title":"COVID-19 vaccine","extract":"A COVID‑19 vaccine is a vaccine designed to induce immunity against SARS-CoV-2, the virus responsible for coronavirus disease 2019 (COVID-19). COVID-19 vaccines help reduce the risk of severe illness, hospitalisation and death from the virus."},"indications":{"approved":[{"name":"Prevention of COVID-19 infection and severe disease caused by SARS-CoV-2"}]},"trialDetails":[{"nctId":"NCT04967807","phase":"NA","title":"Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-08-05","conditions":"Myocardial Injury, Myocarditis, COVID-19 Vaccination","enrollment":57},{"nctId":"NCT04368728","phase":"PHASE2, PHASE3","title":"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-04-29","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":46969},{"nctId":"NCT04367883","phase":"","title":"Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection","status":"RECRUITING","sponsor":"Consorci Sanitari de Terrassa","startDate":"2020-03-01","conditions":"COVID19, Influenza Vaccination, ACE Inhibitors","enrollment":3000},{"nctId":"NCT05265065","phase":"PHASE3","title":"Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-27","conditions":"COVID-19","enrollment":601},{"nctId":"NCT04779827","phase":"NA","title":"Improving Health Equity for COVID-19 Vaccination for At-risk Populations Using Online Social Networks","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2021-05-04","conditions":"Vaccination Refusal, Covid19, Heart Diseases","enrollment":4476},{"nctId":"NCT07279766","phase":"PHASE4","title":"Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2025-12-11","conditions":"COVID-19","enrollment":285000},{"nctId":"NCT05876377","phase":"","title":"Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-10-23","conditions":"SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome","enrollment":1},{"nctId":"NCT06181292","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2023-11-15","conditions":"SARS-CoV2 Infection","enrollment":913},{"nctId":"NCT05142553","phase":"PHASE2","title":"Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2021-11-16","conditions":"COVID-19, SARS-CoV-2 Acute Respiratory Disease","enrollment":887},{"nctId":"NCT06599658","phase":"PHASE2","title":"COVID-19 Booster and IIV Schedule in Immunocompromised Hosts","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2024-11-20","conditions":"COVID 19, Influenza, Rheumatoid Arthritis (RA)","enrollment":660},{"nctId":"NCT07096245","phase":"NA","title":"Conectados: Social Networks and Social Media for Vaccine Uptake","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2025-09-10","conditions":"Vaccination","enrollment":507},{"nctId":"NCT07051031","phase":"PHASE4","title":"COVID-19 Reactogenicity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Marcel Curlin","startDate":"2025-10-01","conditions":"COVID-19","enrollment":1000},{"nctId":"NCT04992195","phase":"","title":"Impact of COVID-19 Vaccines on Cerebrovascular Health","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2021-07-05","conditions":"Stroke, Stroke, Acute, Stroke, Ischemic","enrollment":500},{"nctId":"NCT05415267","phase":"PHASE3","title":"Immunosuppression and COVID-19 Boosters","status":"RECRUITING","sponsor":"Kirby Institute","startDate":"2023-07-21","conditions":"COVID-19","enrollment":320},{"nctId":"NCT06505993","phase":"NA","title":"Addressing COVID-19 Vaccine Hesitancy With Muliti-Level Interventions in Appalachia","status":"SUSPENDED","sponsor":"Marc Kiviniemi","startDate":"2026-09","conditions":"COVID-19, Vaccine Hesitancy","enrollment":2250},{"nctId":"NCT04804072","phase":"NA","title":"INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit","status":"COMPLETED","sponsor":"HIV Prevention Trials Network","startDate":"2021-06-02","conditions":"HIV Infections, Drug Use, Opioid Use","enrollment":447},{"nctId":"NCT04839146","phase":"PHASE1","title":"Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2021-03-11","conditions":"Covid19, Severe Acute Respiratory Syndrome, SARS-CoV-2 Infection","enrollment":45},{"nctId":"NCT07400848","phase":"","title":"Clinical Laboratory Evaluation, Assessment of Symptoms and Recovery in Patients With Post-COVID-19-Vaccination Syndrome","status":"RECRUITING","sponsor":"University of Bern","startDate":"2026-02-15","conditions":"Post-Acute COVID-19 Vaccination Syndrome, Postviral Fatigue","enrollment":200},{"nctId":"NCT03656926","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":169},{"nctId":"NCT07387211","phase":"NA","title":"Study SARS-CoV-2-CZ-PREVAL-II - Arm of the Olomouc Region","status":"COMPLETED","sponsor":"The Institute of Molecular and Translational Medicine, Czech Republic","startDate":"2022-01-18","conditions":"SARS-CoV-2, SARS-CoV-2 (COVID-19) Infection","enrollment":2484},{"nctId":"NCT05046002","phase":"","title":"COVID-19 Vaccine-induced Inflammatory Heart Disease Prevalence Registry","status":"RECRUITING","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2021-08-11","conditions":"Myocarditis, Pericarditis","enrollment":400},{"nctId":"NCT05262920","phase":"NA","title":"Promoting Self-Management of Breast and Nipple Pain With Technology (PROMPT) for Breastfeeding Women Study","status":"COMPLETED","sponsor":"University of Connecticut","startDate":"2022-03-16","conditions":"Breastfeeding, Exclusive, Pain, Acute, Maternal Distress","enrollment":250},{"nctId":"NCT06036134","phase":"NA","title":"Reducing COVID-19 Vaccine Hesitancy Among Hispanic Parents","status":"COMPLETED","sponsor":"Arizona State University","startDate":"2023-12-01","conditions":"Vaccine-Preventable Diseases, COVID-19 Pandemic, Health-Related Behavior","enrollment":80},{"nctId":"NCT05078905","phase":"","title":"Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-10-13","conditions":"COVID-19, Vaccination, Healthy Volunteer","enrollment":1200},{"nctId":"NCT06547814","phase":"NA","title":"COVID-19 Vaccine Hesitancy Counseling Intervention for Pharmacists: A Stepped-Wedge Trial","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2024-08-05","conditions":"COVID-19","enrollment":20},{"nctId":"NCT06503900","phase":"PHASE4","title":"Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-09-12","conditions":"Birth Outcomes, Safety, Adverse Event Following Immunization","enrollment":98},{"nctId":"NCT05302908","phase":"NA","title":"COVID-19 Testing and Vaccination Among Spanish Speakers","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2023-02-09","conditions":"COVID-19, Vaccinations","enrollment":274},{"nctId":"NCT05766189","phase":"NA","title":"Wastewater Surveillance to Boost COVID-19 Vaccine Uptake","status":"COMPLETED","sponsor":"Syracuse University","startDate":"2023-03-01","conditions":"Vaccination, Wastewater Surveillance","enrollment":100000},{"nctId":"NCT06613984","phase":"","title":"Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-10-11","conditions":"COVID-19 Vaccination","enrollment":660},{"nctId":"NCT05926544","phase":"NA","title":"COVID-19 Vaccine Hesitancy Counseling Intervention for Pharmacists","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2023-10-04","conditions":"COVID-19","enrollment":16},{"nctId":"NCT05541861","phase":"PHASE1","title":"Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-11-08","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":383},{"nctId":"NCT05077254","phase":"PHASE2","title":"COVID Protection After Transplant-Immunosuppression Reduction","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-12-06","conditions":"Kidney Transplant Recipients, Liver Transplant Recipients","enrollment":48},{"nctId":"NCT05050461","phase":"NA","title":"Immune Response After SARS-CoV-2 (COVID-19) Vaccination in a Context of Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Versailles Hospital","startDate":"2021-11-15","conditions":"Non-hodgkin Lymphoma,B Cell, Vaccination Failure","enrollment":120},{"nctId":"NCT04872738","phase":"","title":"Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-05-07","conditions":"Breast Cancer Related Lymphedema, Covid19","enrollment":714},{"nctId":"NCT07074171","phase":"NA","title":"Examining How a Text Message-based Educational Intervention Influences COVID-19 Testing","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2023-04-03","conditions":"COVID-19 Testing Behaviors","enrollment":384},{"nctId":"NCT04750720","phase":"NA","title":"Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection","status":"COMPLETED","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2020-08-27","conditions":"Covid19, SARS-CoV-2","enrollment":187},{"nctId":"NCT04442048","phase":"PHASE3","title":"Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2020-10-01","conditions":"Cancer, Covid-19","enrollment":195},{"nctId":"NCT04760704","phase":"","title":"Covid-19 Vaccine Response in Elderly Subjects","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2021-02-18","conditions":"Covid19 Vaccine","enrollment":264},{"nctId":"NCT05919472","phase":"NA","title":"Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women","status":"COMPLETED","sponsor":"Nicole Stoffel","startDate":"2023-07-01","conditions":"Iron Deficiency Anemia","enrollment":180},{"nctId":"NCT04952766","phase":"PHASE4","title":"Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults","status":"COMPLETED","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2021-03-26","conditions":"Kidney Transplant, Myeloma, Cancer","enrollment":196},{"nctId":"NCT04894253","phase":"","title":"Immune Response to SARS-CoV-2 Vaccination in Systemic Lupus","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2021-06-07","conditions":"Systemic Lupus","enrollment":7},{"nctId":"NCT05228275","phase":"","title":"Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2022-04-08","conditions":"COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm","enrollment":549},{"nctId":"NCT04411602","phase":"PHASE1","title":"Intermediate IND Severe Illness COVID-19 CP","status":"WITHDRAWN","sponsor":"Henry Ford Health System","startDate":"2020-04-07","conditions":"Severe Acute Respiratory Syndrome, COVID","enrollment":""},{"nctId":"NCT04939402","phase":"NA","title":"SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the UZ Brussel Following COVID-19 Vaccination Using an Adenoviral Vector","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2021-05-05","conditions":"SARS-CoV-2, Covid19","enrollment":200},{"nctId":"NCT05234372","phase":"NA","title":"MiVacunaLA: an Intervention to Improve COVID-19 Vaccination Behaviors Among Latinos","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2022-06-01","conditions":"COVID-19 Pandemic","enrollment":468},{"nctId":"NCT06469788","phase":"NA","title":"Testimonials and Navigation in Rheumatology","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2024-12-18","conditions":"Rheumatologic Disease, Autoimmune Diseases","enrollment":1170},{"nctId":"NCT04939519","phase":"NA","title":"SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Vaccination Rates Among Utah Community Health Centers","status":"COMPLETED","sponsor":"University of Utah","startDate":"2021-03-29","conditions":"Covid19","enrollment":65300},{"nctId":"NCT02081326","phase":"PHASE2","title":"Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2015-06","conditions":"Diabetes Mellitus, Type One, Diabetes Mellitus, Type I, Autoimmune Diabetes","enrollment":150},{"nctId":"NCT04983251","phase":"","title":"Women s Health Awareness Community Resiliency, Environmental Action and Collaborations for Health (REACH) Equity","status":"RECRUITING","sponsor":"National Institute of Environmental Health Sciences (NIEHS)","startDate":"2023-06-30","conditions":"Mental Health","enrollment":700},{"nctId":"NCT06851611","phase":"PHASE1","title":"The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus","status":"COMPLETED","sponsor":"Rokote Laboratories Finland Oy","startDate":"2025-01-21","conditions":"COVID19, Sars-Cov-2","enrollment":40},{"nctId":"NCT05655351","phase":"EARLY_PHASE1","title":"Effect of a Vaccination Against COVID-19 on Monocyte Production of Oxygenated Derivatives.","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2022-12-21","conditions":"CORONAVIRUS INFECTIONS","enrollment":30},{"nctId":"NCT04780659","phase":"PHASE4","title":"COVID-19 Vaccination of Immunodeficient Persons (COVAXID)","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2021-02-23","conditions":"Covid19","enrollment":539},{"nctId":"NCT05543993","phase":"","title":"COVID Booster in Pregnancy and Lactation","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2022-09-29","conditions":"COVID-19","enrollment":150},{"nctId":"NCT05212948","phase":"PHASE3","title":"A Study of S-268019 for the Prevention of COVID-19","status":"COMPLETED","sponsor":"Shionogi","startDate":"2021-12-25","conditions":"SARS-CoV-2","enrollment":9902},{"nctId":"NCT06168019","phase":"","title":"Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India","status":"RECRUITING","sponsor":"Boston University","startDate":"2023-12-26","conditions":"Influenza, COVID-19, SARS-COV-2 Infection","enrollment":10000},{"nctId":"NCT04830046","phase":"","title":"Covid-19 Vaccine Responsiveness in MM and Waldenstrom","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-04-15","conditions":"Multiple Myeloma, Waldenstrom Macroglobulinemia, Immune System Disorder","enrollment":146},{"nctId":"NCT04370119","phase":"","title":"Screening for COVID-19 and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers","status":"COMPLETED","sponsor":"University Medicine Greifswald","startDate":"2020-04-27","conditions":"SARS-CoV-2","enrollment":1092},{"nctId":"NCT05032976","phase":"","title":"Korea Comirnaty Post-marketing Surveillance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-03-18","conditions":"COVID-19, Vaccines, Adverse Effects","enrollment":12000},{"nctId":"NCT06128928","phase":"NA","title":"Connecting Friends and Health Workers to Boost COVID-19 Vaccination in Latino Communities","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-07-08","conditions":"COVID-19, Vaccine","enrollment":900},{"nctId":"NCT05012943","phase":"PHASE2, PHASE3","title":"The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)","status":"COMPLETED","sponsor":"Vinbiocare Biotechnology Joint Stock Company","startDate":"2021-08-15","conditions":"COVID-19 Vaccines","enrollment":19474},{"nctId":"NCT07128095","phase":"","title":"COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise","status":"RECRUITING","sponsor":"Indiana University","startDate":"2025-08-22","conditions":"COVID-19, Sleep, Immunization; Infection","enrollment":100},{"nctId":"NCT06605625","phase":"","title":"Vaccine Responses in Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2022-11-04","conditions":"Viral Vaccines","enrollment":250},{"nctId":"NCT05960097","phase":"PHASE2","title":"A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-08-01","conditions":"SARS-CoV-2, COVID-19","enrollment":692},{"nctId":"NCT05074433","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-10-25","conditions":"Immunocompromised","enrollment":66},{"nctId":"NCT07213141","phase":"","title":"Incidence of Graves' Disease After COVID-19 Vaccination","status":"ACTIVE_NOT_RECRUITING","sponsor":"Laura ICONARU","startDate":"2022-11-08","conditions":"Graves Disease","enrollment":161},{"nctId":"NCT06579222","phase":"NA","title":"Comorbidity Management in Rheumatic Disease.","status":"RECRUITING","sponsor":"Western University, Canada","startDate":"2025-05-01","conditions":"Rheumatoid Arthritis, Comorbidities and Coexisting Conditions","enrollment":199},{"nctId":"NCT06647654","phase":"","title":"Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-08-26","conditions":"Respiratory Syncytial Virus, Respiratory Tract Diseases","enrollment":1},{"nctId":"NCT05710783","phase":"PHASE2, PHASE3","title":"Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster.","status":"COMPLETED","sponsor":"Laboratorio Avi-Mex, S.A. de C.V.","startDate":"2022-11-09","conditions":"SARS-CoV-2 Infection","enrollment":4065},{"nctId":"NCT06452654","phase":"PHASE4","title":"Anti-viral Action Against Type 1 Diabetes Autoimmunity","status":"RECRUITING","sponsor":"Technical University of Munich","startDate":"2024-05-08","conditions":"Diabetes Mellitus, Type 1","enrollment":2252},{"nctId":"NCT05534009","phase":"","title":"Health Care Workers Cohort Study in the EuCARE Project (EuCARE-HCW)","status":"RECRUITING","sponsor":"Euresist Network GEIE","startDate":"2022-04-01","conditions":"COVID-19","enrollment":1800},{"nctId":"NCT05866237","phase":"NA","title":"COVID-19 Vaccine Uptake Amongst Underserved Populations in East London","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2023-11-28","conditions":"COVID-19, Influenza, Vaccination Refusal","enrollment":5903},{"nctId":"NCT06776367","phase":"","title":"Project REMOTE (REimagining Measurements and Operations of Translational Endpoints)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2024-12-20","conditions":"COVID-19","enrollment":4000},{"nctId":"NCT05303402","phase":"PHASE2, PHASE3","title":"A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2022-05-12","conditions":"SARS CoV 2 Infection","enrollment":241},{"nctId":"NCT06698497","phase":"NA","title":"Boosting COVID-19 Vaccination Uptake Using Wastewater Surveillance","status":"COMPLETED","sponsor":"Syracuse University","startDate":"2024-09-13","conditions":"Vaccine Uptake","enrollment":40},{"nctId":"NCT05869968","phase":"","title":"SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2023-03-31","conditions":"Spinal Cord Injuries, Traumatic Spinal Cord Injury, Healthy Controls","enrollment":140},{"nctId":"NCT06062056","phase":"NA","title":"Motivational Interviewing for Vaccine Uptake in Latinx Adults","status":"TERMINATED","sponsor":"Boston College","startDate":"2023-10-02","conditions":"Vaccine Hesitancy","enrollment":3698},{"nctId":"NCT06156215","phase":"NA","title":"PROmotion of COVID-19 BOOSTer VA(X)Ccination in the Emergency Department - PROBOOSTVAXED","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2024-01-19","conditions":"COVID-19","enrollment":919},{"nctId":"NCT04794829","phase":"","title":"Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-19","conditions":"Influenza, COVID-19","enrollment":150},{"nctId":"NCT04870411","phase":"","title":"Immunological Response to COVID-19 Vaccine in Patients With Autoimmune and Inflammatory Diseases Treated With Immunosuppressants and/or Biologics","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-05-12","conditions":"Autoimmune Diseases, Inflammatory Disorder","enrollment":78},{"nctId":"NCT06119854","phase":"NA","title":"Brief Digital Intervention to Increase COVID-19 Vaccination Among Individuals With Anxiety or Depression","status":"COMPLETED","sponsor":"City University of New York, School of Public Health","startDate":"2024-04-15","conditions":"Misinformation, Vaccine Hesitancy, Anxiety","enrollment":1419},{"nctId":"NCT06199934","phase":"","title":"Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-09-11","conditions":"SARS-CoV-2, COVID-19 Vaccines","enrollment":19853610},{"nctId":"NCT06038617","phase":"PHASE4","title":"Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-10-30","conditions":"Fever After Vaccination, Fever, Seizures Fever","enrollment":344},{"nctId":"NCT05543642","phase":"PHASE4","title":"The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2022-10-11","conditions":"Rheumatic Diseases","enrollment":129},{"nctId":"NCT05120869","phase":"NA","title":"Healthcare Provider Human Papillomavirus Education and Professional Skills Intervention","status":"COMPLETED","sponsor":"University of Texas, El Paso","startDate":"2023-12-22","conditions":"Health Personnel Attitude, Health Knowledge, Attitudes, Practice","enrollment":178},{"nctId":"NCT04915820","phase":"NA","title":"Iron and COVID-19 Vaccine Response","status":"COMPLETED","sponsor":"Jomo Kenyatta University of Agriculture and Technology","startDate":"2021-05-29","conditions":"Iron Deficiency Anemia, Vaccine Response Impaired, COVID-19 Vaccine","enrollment":121},{"nctId":"NCT05570630","phase":"NA","title":"VAX-MOM COVID-19: Increasing Maternal COVID-19 Vaccination","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2022-10-21","conditions":"Immunization; Infection, Pregnancy Related, COVID-19","enrollment":6911},{"nctId":"NCT05000216","phase":"PHASE2","title":"COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-13","conditions":"Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris","enrollment":258},{"nctId":"NCT04757883","phase":"","title":"Immunological Follow-up After SARS CoV2 Vaccination in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2021-02-02","conditions":"Kidney Transplant Recipients","enrollment":37},{"nctId":"NCT04951336","phase":"NA","title":"RCT of Mushroom Based Natural Product to Enhance Immune Response to COVID-19 Vaccination","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2021-06-10","conditions":"COVID-19 Vaccination","enrollment":90},{"nctId":"NCT06057064","phase":"PHASE2","title":"Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-09-29","conditions":"COVID-19, SARS-CoV-2","enrollment":116},{"nctId":"NCT04761822","phase":"PHASE2","title":"COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-07","conditions":"SARS-CoV Infection, COVID-19, Allergic Reaction","enrollment":746},{"nctId":"NCT04297917","phase":"PHASE1","title":"First in Human Study of ChAdOx1-HBV in Healthy Participants and Participants With Chronic hepB Infection","status":"COMPLETED","sponsor":"Barinthus Biotherapeutics","startDate":"2019-02-10","conditions":"Hepatitis B, Healthy","enrollment":47},{"nctId":"NCT06805656","phase":"PHASE2","title":"Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals","status":"NOT_YET_RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2025-09-01","conditions":"Hiv, HIV I Infection","enrollment":70},{"nctId":"NCT05379478","phase":"","title":"Immune Responses to COVID-19 Infection or Vaccination","status":"COMPLETED","sponsor":"Aditxt, Inc.","startDate":"2020-12-01","conditions":"COVID-19","enrollment":403},{"nctId":"NCT06646406","phase":"NA","title":"Evaluation of a Multilevel Intervention on Adult COVID-19 and Influenza Vaccination Rate","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2024-10-21","conditions":"COVID-19 Immunisation, Influenza Vaccine","enrollment":114165},{"nctId":"NCT06189053","phase":"","title":"A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2022-04-30","conditions":"Myocarditis","enrollment":1500},{"nctId":"NCT06113692","phase":"","title":"A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-03-31","conditions":"Myocarditis, Pericarditis","enrollment":1169},{"nctId":"NCT05863884","phase":"NA","title":"RADx-UP- Impact of Community Health Worker Deployment","status":"COMPLETED","sponsor":"Morehouse School of Medicine","startDate":"2022-02-11","conditions":"Diabetes, COVID-19, Community Health Workers","enrollment":87},{"nctId":"NCT06821100","phase":"PHASE1","title":"Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2024-12-02","conditions":"Vaccine Response, COVID-19 Vaccine, Immune Response to Covid 19 Vaccination","enrollment":75},{"nctId":"NCT04969263","phase":"PHASE2","title":"COVID-19 Protection After Transplant Pilot Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-10","conditions":"Kidney Transplant Recipients","enrollment":81}],"_emaApprovals":[],"_faersSignals":[{"count":23,"reaction":"COVID-19"},{"count":12,"reaction":"PAIN"},{"count":8,"reaction":"ARTHRALGIA"},{"count":8,"reaction":"DIARRHOEA"},{"count":8,"reaction":"FATIGUE"},{"count":7,"reaction":"PSORIASIS"},{"count":6,"reaction":"THERAPEUTIC PRODUCT EFFECT DECREASED"},{"count":5,"reaction":"DIZZINESS"},{"count":5,"reaction":"HEADACHE"},{"count":5,"reaction":"NAUSEA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["the monovalent Omicron XBB.1.5 COVID-19 mRNA vaccination","Moderna mRNA-1273 vaccine","Moderna (mRNA-1273)","Pfizer (BTN162b2)","Janssen (Ad26.COV2.S)"],"phase":"marketed","status":"active","brandName":"COVID-19 vaccination","genericName":"COVID-19 vaccination","companyName":"University Medical Center Groningen","companyId":"university-medical-center-groningen","modality":"Biologic","firstApprovalDate":"","aiSummary":"COVID-19 vaccines train the immune system to recognize and neutralize the SARS-CoV-2 virus by inducing antibody and T-cell responses against viral antigens. Used for Prevention of COVID-19 infection and severe disease caused by SARS-CoV-2.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}